SRR25617835
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.360
- KRAS_SIGNALING_DN+0.210
- SPERMATOGENESIS+0.210
- BILE_ACID_METABOLISM+0.090
- ANGIOGENESIS+0.080
- XENOBIOTIC_METABOLISM+0.070
- APICAL_SURFACE+0.040
- MYC_TARGETS_V2+0.020
- CHOLESTEROL_HOMEOSTASIS+0.000
- E2F_TARGETS-0.020
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.370
- ESTROGEN_RESPONSE_EARLY-0.360
- APOPTOSIS-0.350
- INTERFERON_ALPHA_RESPONSE-0.350
- INTERFERON_GAMMA_RESPONSE-0.340
- P53_PATHWAY-0.320
- UV_RESPONSE_DN-0.320
- ANDROGEN_RESPONSE-0.310
- UNFOLDED_PROTEIN_RESPONSE-0.310
- MYC_TARGETS_V1-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR4976608 | — | D | 0.909 |
| 2 | SRR26320083 | — | — | 0.902 |
| 3 | sclc1081_S46.txt | — | cohortSC | 0.895 |
| 4 | SRR12202488 | — | — | 0.891 |
| 5 | SRR12696749 | — | — | 0.888 |
| 6 | TCGA-E7-A7PW-01A-11R-A352-07 | — | — | 0.888 |
| 7 | SRR26320081 | — | — | 0.887 |
| 8 | SRR8943038 | — | — | 0.884 |
| 9 | SRR12696788 | — | — | 0.882 |
| 10 | sclc265549_S73.txt | — | cohortMD1 | 0.881 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 8 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.360 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.210 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.210 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.090 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.080 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.070 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.040 | Temsirolimus | — uncovered |
| MYC_TARGETS_V2 | 0.020 | Idelalisib | — uncovered |